BioSpace News Archive

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company’s third quarter 2021 financial results on Thursday, November 4, 2021 after the close of U.S. financial markets.

Lucira Health, Inc., a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, announced that the company will report third quarter 2021 financial results on, Thursday, November 11, 2021.

Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced that the company’s Chief Scientific Officer, Eric Murphy, Ph.D., will step down from that role on December 3, 2021 to pursue a new opportunity.

SOPHiA GENETICS SA announced the company will be participating virtually in the following investor conferences.

Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced the Company will release financial results for the third quarter of 2021 after the close of trading on Thursday, November 11, 2021.

Singular Genomics Systems, Inc., a company focused on delivering genomic technologies for the advancement of science and medicine, today announced that it will report financial results for the third quarter of 2021 after the market close on Tuesday, November 9, 2021.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2021 financial results and provided a corporate update.

HeartFlow, Inc. welcomed new clinical practice guidelines from the American College of Cardiology and American Heart Association that recognized the HeartFlow FFRct Analysis with Class of Recommendation 2a, identifying it as an important tool for diagnosing coronary artery disease and guiding decision-making regarding the use of revascularization procedures such as coronary stenting or bypass surgery.

LeMaitre, a provider of vascular devices, implants and services, reported Q3 2021 results, announced an $0.11/share quarterly dividend and provided guidance.